Related references
Note: Only part of the references are listed.Testing against a high-dimensional alternative in the generalized linear model: asymptotic type I error control
Jelle J. Goeman et al.
BIOMETRIKA (2011)
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines
Lynnette Fernandez-Cuesta et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors
Espen Enerly et al.
PLOS ONE (2011)
Cooperative interaction between retinoic acid receptor-α and estrogen receptor in breast cancer
Caryn S. Ross-Innes et al.
GENES & DEVELOPMENT (2010)
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Daniele Merico et al.
PLOS ONE (2010)
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
X. B. Trinh et al.
BRITISH JOURNAL OF CANCER (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
STRING 8-a global view on proteins and their functional interactions in 630 organisms
Lars J. Jensen et al.
NUCLEIC ACIDS RESEARCH (2009)
Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2
Gopal Dhar et al.
CANCER RESEARCH (2008)
Comparative evaluation of gene-set analysis methods
Qi Liu et al.
BMC BIOINFORMATICS (2007)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Bjorn Naume et al.
MOLECULAR ONCOLOGY (2007)
Improving gene set analysis of microarray data by SAM-GS
Irina Dinu et al.
BMC BIOINFORMATICS (2007)
Surveillance mechanism linking Bub1 loss to the p53 pathway
Ole V. Gjoerup et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen
Philippe Bertheau et al.
PLOS MEDICINE (2007)
Adjusting batch effects in microarray expression data using empirical Bayes methods
W. Evan Johnson et al.
BIOSTATISTICS (2007)
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Anita Langerod et al.
BREAST CANCER RESEARCH (2007)
The versatile interactions of p53 with DNA: when flexibility serves specificity
E. Kim et al.
CELL DEATH AND DIFFERENTIATION (2006)
Estrogen receptor-α binds p53 tumor suppressor protein directly and represses its function
WS Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
M Olivier et al.
CLINICAL CANCER RESEARCH (2006)
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
LD Miller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells
YY Liang et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Extending survival with chemotherapy in metastatic breast cancer
J O'Shaughnessy
ONCOLOGIST (2005)
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
VJ Bardou et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Mutant p53 can delay growth arrest and loss of CDK2 activity in senescing human fibroblasts without reducing p21WAF1 expression
F Wyllie et al.
EXPERIMENTAL CELL RESEARCH (2003)
KEGG: Kyoto Encyclopedia of Genes and Genomes
M Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
